Monitoring of cardiovascular risk factors in patients with diabetes type 2

Czech version

Authors: B. Petrlová; H. Rosolová; J. Šimon; F. Šefrna; P. Šifalda; I. Šípová
Authors‘ workplace: II. interní klinika Lékařské fakulty UK a FN Plzeň, přednosta prof. MUDr. Jan Filipovský, CSc.
Published in: Vnitř Lék 2009; 55(9): 812-818
Category: 80th Birthday - prof. MUDr. Miloš Štejfa, DrSc., FESC

Overview

The control of basic cardiovascular risk factors was examined in a sample of 415 diabetes type 2 patients, aged 66 ± 10 years, with a 9.4 ± 8 years long history of diabetes, both genders represented proportionally; 95% of the sample were hypertensive. The recommended blood pressure value was achieved by 13% males and 17% females. Antihypertensive monotherapy was indicated in 40% of the sample. Renin-angiotensin-aldosteron system inhibitors were prescibed to 90% of the sample. The fasting glycaemia ≤ 6 mmol/L were achieved in 10% males and 11% females; glycosilated hemoglobin < 4.5 % in 20% males and 24% females; 60% of the sample had antidiabetic pharmacotherapy – 44% males and 48 % females used metformin. Total fasting plasma cholesterol < 4.5 mmol/L was achieved in 31% males and 23% females; LDL-cholesterol < 2.5 mmol/L was achieved in 31% males and 41% females. The target values for diabetics in secondary prevention of cardiovaskular diseases or with subclinical atherosclerosis was achieved in 13% of the sample. Statins were prescribed in 60% of the sample, fibrates in 4%. Only 2 females achieved all the target values. Hypolipidemic and antihypertensive drug therapy is unsatisfactory; there is certainly a big potential in life style changes among the diabetic patients.

Key words:
diabetes mellitus type 2 – cardiovascular risk factors

Sources

1. Cífková R, Býma S, Češka R et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Společná doporučení českých odborných společností. Vnitř Lék 2005; 51: 1021–1036.

2. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidémií v dospělosti vypracovaného výborem České společnosti pro aterosklerózu. Cor Vasa 2007; 49 (Suppl): K73–K86.

3. Widimský J Jr, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze – verze 2007. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2008; 54: 101–118.

4. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypers 2007; 25: 1105–1187.

5. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39. BMJ 1998; 317: 713–720.

6. Standardy České diabetologické společnosti. Available from: http://www.diab.cz/modules.php?name=Standardy.

7. Rosolová H, Petrlová B, Šimon J et al. Makrovaskulární a mikrovaskulární komplikace u diabetiků 2. typu. Vnitř Lék 2008; 54: 229–237.

8. Souček M, Widimský J, Lánská V. Control of hypertension in patients with hypertension, diabetes, and impaired fasting glucose by Czech primary care physicians. Kidney Blood Press Res 2006; 29: 366–372.

9. Škrha J. Diabetes mellitus 2002 v České republice – Epidemiologická studie. DMEV 2005; 8: 5–12.

10. Kindermann M, Adam O, Werner N et al. EUROASPIRE III Study. Clin Res Cardiol 2007; 96: 767–786.

11. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE substudy. Lancet 2000; 355: 253–259.

12. Lidholm LH, Ibsen H, Dahlöf B et al. LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–1010.

13. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Effect of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–840.

14. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–1951.

15. Grundy SM, Vega GL, Yuan Z et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidaemia (the SAFARI trial). Am J Cardiol 2005; 95: 462–468.

16. Denke M, Pearson T, McBride P et al. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res 2006; 3: 93–102.

17. Keech A, Simes RJ, Barter P et al. FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849–1861.

18. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687–1697.

19. Fruchart JC, Sacks FM, Hermans MP et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008; 5: 319–335.

20. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type II diabetes (UKPDS 34). Lancet 1998; 352: 854–865.

21. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572.

22. Gerstein HC, Miller ME, Byington RP et al. Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD). Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559.

23. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–139.

24. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.

25. Belch J, MacCuish A, Campbell I et al. POPADAD study group. The prevention of progression of arterial asymptomatic peripheral arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with disabetes and asymptomatic peripheral diasease. BMJ 2008; 337.